Antibody Business Development Clinical Development Genetic Disease 
Drug Discovery World
AUGUST 28, 2023
Could it be possible to prevent genetic diseases? PH: As well as starting clinical trials with our most advanced programme, SAM001, we have two more highly promising programmes that we want to advance to the clinic in the next year or two. DS: What’s next for the company’s pipeline? LinkedIn profile.
The Pharma Data
DECEMBER 8, 2020
Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost. Nuance Pharma .
Expert insights. Personalized for you.
52 
Let's personalize your content